Renal impairment in patients with inflammatory bowel disease: Association with aminosalicylate therapy?

Clinical Nephrology

Volumn 61, Issue 2, 2004, Pages 83-89

  Elseviers, M M ^a   D'Haens, G ^b   Lerebours, E ^c   Plane, C ^d   Stolear, J C ^e   Riegler, G ^f   Capasso, G ^f   Van Outryve, M ^a   Mishevska Mukaetova, P ^g   Djuranovic, S ^h   Pelckmans, P ^a   De Broe, Marc E ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Rouen Hospital   (France)

^d University Hospital Bethune   (France)

^e Medical Chirurgical Institute   (Belgium)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^h University of Belgrad

Author keywords

5 aminosalycilic acid; Inflammatory bowel disease; Renal impairment; Tubulo interstitial nephritis

Indexed keywords

AMINOPHENOL; MESALAZINE; PHENACETIN; SALAZOSULFAPYRIDINE; SALICYLIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; COLITIS; CONTROLLED STUDY; CREATININE CLEARANCE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG USE; ENTERITIS; EUROPE; FEMALE; HUMAN; INTERSTITIAL NEPHRITIS; INTESTINE RESECTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; PUBLICATION; QUESTIONNAIRE; REGISTER; SEX RATIO; STOMA; ULCERATIVE COLITIS;

EID: 10744227275     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP61083     Document Type: Article

References (22)

1. Baginski P, Tandar A, Black RM 2000 Mesalamine (5-ASA, Asacol) induced end-stage renal disease. J Am Soc Nephrol 11: 55A (abstract)
2. Calder IC, Funder CC, Green CR, Ham KN, Tange JD 1972 Nephrotoxic lesions from 5-aminosalicylic acid. Br Med J 1: 152-154
3. Calvino J, Romero R, Pintos E, Losada E, Novoa D, Güimil D, Mardaras J, Sanchez-Guisande D 1998 Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin Nephrol 49: 265-267
4. Clemett D, Markham A 2000 Prolonged-release mesalazine. A review of its therapeutic potential in ulcerative colitis and Crohn's disease. Drugs 59: 929-956
5. Cockcroft DW, Gault MH 1976 Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
6. De Broe ME, Stolear J-C, Nouwen EJ, Elseviers MM 1996 Mesalazine and chronic interstitial nephritis: is there a role for urinary markers to detect early changes? In: Goebel H, Sutherland L (eds) Pharmacokinetics and Safety Profile of Mesalazine 1997. Adis Int Ltd, Chester, pp 42-52
7. Dwarakanath AD, Michael J, Allan RN 1992 Sulphasalazine induced renal failure. Gut 33: 1006-1007
8. Elseviers MM, De Broe ME 2001 What can nephrologists learn from epidemiology? J Nephrol 14: 88-92
9. Elseviers MM, Verpooten GA, De Broe ME, De Backer GG 1987 Interpretation of creatinine clearance (letter to the Editor). Lancet 1: 457
10. Glickman RM 1996 Inflammatory bowel disease (ulcerative colitis and Crohn's disease). In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds) Harrison's Principles of Internal Medicine (13th ed). pp, 1403-1416
11. Herrlinger KR, Noftz MK, Fellermann K, Schmidt K, Steinhoff J, Stang EF 2001 Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA use. Aliment Pharmacol Ther 15: 363-369
12. Izzedine H, Simon J, Piette A-M, Lucsko M, Baumelou A, Charitanski D, Kernaonet E, Baglin A-C, Deray G, Beaufils H 2002 Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology 123: 1436-1440
13. Järnerot G 1994 New salicylates as maintenance treatment in ulcerative colitis. Gut 35: 1155-1158
14. McCallum D, Smith L, Harley F, Yiu V 1997 IgA nephropathy and thin basement membrane disease in association with Crohn disease. Pediatr Nephrol 11: 637-640
15. Moayyedi P, Fletcher S, Harnder P, Axon ATR, Brownjohn A 1995 Mesangiocapillary glomerulonephritis associated with ulcerative colitis: case report of two patients. Nephrol Dial Transplant 10: 1923-1924
16. Mulder CJJ, van den Hazel SJ 1998 Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mediat Inflamm 7: 135-136
17. Schreiber S, Hämling J, Zehnter E, Howaldt S, Daerr W Raedler A, Kruis W 1997 Renal tubular dysfunction in patients with inflammatory bowel disease treated with ammosalicylate. Gut 40: 761-766
18. Shaer AJ, Stewart L, Cheek DE, Hurray D, Self SE 2003 IgA antiglomerular basement membrane nephritis associated with Crohn's disease: a case report and review of glomerulonephritis in inflammatory bowel disease. Am J Kidney Dis 51: 1097-1109
19. Stein RB, Hanauer SB 2000 Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 23: 429-448
20. Stolear JC, Georges B, Gossun A, Ros Ph, Nouwen EJ, De Broe ME 1996 Néphrite interstitiëlle associée à la Mésalazine. Confrontations anatomo-cliniques en pathologie renale et vasculaire. Hôpital Tenon, Paris
21. Wilcox GM, Aretz HT, Roy MA, Roche JK 1990 Glomerulonephritis associated with inflammatory bowel disease. Gastroenterology 98: 786-791
22. World MJ, Stevens PE, Ashton MA, Rainford DJ 1996 Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 11: 614-621